Frequently Asked Questions - Childhood Solid Tumor Network

  1. The request must be processed and approved by Michael Dyer, PhD; Dr. Alberto Pappo, MD; and the Childhood Solid Tumor Network (CSTN) committee. After approval, a Material Transfer Agreement (MTA) will be sent to your institution for signature and execution. If there is a need for further clarification prior to approval, we will contact you directly.

    The typical process is as follows:

    • Request is submitted
    • CSTN approves request
    • CSTN sends MTA/CDA to requesting institution
    • Requesting institution signs MTA/CDA, sends to CSTN for signature
    • CSTN confirms shipping details and ships samples
    • Request is closed
  2. Our goal is to share samples for timely use in order to drive more rapid discovery in the field, while minimizing the risk that valuable samples may be “stockpiled” for possible future use. We also prefer to keep numbers small to reduce the risk of loss or damage incurred by shipping large numbers of cryovials.

  3. The timeline depends on your institution and on the time required to get the MTA signed and executed. Once the MTA is signed we will contact you within a week and confirm shipment details.

  4. The consent form under which the patient tumor samples were collected stipulates that all samples be de-identified and sent out under an MTA.

  5. No. The CSTN actively tracks samples that have been distributed so that we may contact investigators should updated information about the sample become available. Please encourage any interested research colleagues to contact us directly by filling out a request form, and we will be happy to assist.

  6. A CDA, which covers both the requester and CSTN, allows us to freely share unpublished data to further the field.

  7. Please acknowledge the Childhood Solid Tumor Network and cite Stewart, E., et al., The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Dev. Biol. (2015)

  8. Enter the question in the comment section of the request form when you initially submit it, or send an email to

  9. Yes. The request can consist of both xenografts and cell lines. We ask that you restrict your requests to five of each sample type.

  10. No. We have been focused on propagating the xenografts and banking them down for sharing. In the future we may create cell lines from these samples.

  11. Yes. Primer information and genotyping SOPs will be emailed to you when the GEMMs are sent.

  12. For cell lines, you will receive the sample, media conditions under which to grow it and its PowerPlex® ID. For xenografts, you will receive the sample, media conditions and SOPs for implantation, freezing and thawing. You will also receive a sheet with specific information about the tumor sample (phenotype, gene information, etc.). For GEMMs, you will receive the GEMMs, primer information and SOPs for genotyping.

  13. You can subscribe to our newsletter to receive regular updates on new resources, data and advances emerging from the CSTN. We also share information about relevant clinical trials.


About the Childhood Solid Tumor Network

Childhood solid tumors are often difficult to study and treat because they are rare and originate in the complex biological context of developing organs. The CSTN was established to disseminate resources and data that have been developed at St. Jude Children’s Research Hospital, with the aim of stimulating basic research and speeding translation to the clinic.

The effort was launched in 2013 by Howard Hughes Medical Institute investigator Michael Dyer, PhD, of St. Jude Developmental Neurobiology, and Alberto Pappo, MD, of St. Jude Oncology.

For more information, contact us:


For updates on COVID-19, please read.